HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

48.440

-0.700-1.42%

Volume:7.71M

Turnover:381.01M

Market Cap:321.50B

PE:35.07

High:51.000

Open:49.740

Low:48.280

Close:49.140

52wk High:91.880

52wk Low:43.020

Shares:6.64B

HK Float Shares:258.00M

Volume Ratio:1.56

T/O Rate:2.99%

Dividend:0.23

Dividend Rate:0.48%

EPS(LYR):1.381

ROE:12.46%

ROA:7.02%

PB:4.26

PE(LYR):35.07

PS:8.77

Loading ...

Overview Company News Filings

Movement Alert｜HENGRUI PHARMA Rises 3.2% in Regular Trading, Core ADC Pipeline Drug Included in Breakthrough Therapy Designation List

Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List

MT Newswires Live

Hengrui Pharma Gets China Nod for Two Indications of Hetrombopag Olamine Tablets

MT Newswires Live

Jiangsu Hengrui Pharmaceuticals Co - Nmpa Approves Two New Indications for Hetrombopag Olamine Tablets

THOMSON REUTERS

Jiangsu Hengrui Pharmaceuticals Secures Regulatory Nod for Two New Indications of Hetrombopag Olamine Tablets

Movement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress

China Accepts Hengrui Pharma Unit's Marketing Application for Diabetes Drug

MT Newswires Live

AH Share Premium Rankings as of September 9 Trading Close

Hengrui Pharma Sets 24 Sep 2026 EGM to Vote on Dual Employee Share Schemes and 10% H-Share Buyback Mandate

Bulletin Express

Hengrui Pharma Seeks Approval for 2026 Dual-Class Incentive Plans and 10% H-Share Buy-Back Authority

Bulletin Express

Hengrui Pharma Wins China Clinical Trial Nod For Two Weight Management Products

MT Newswires Live

Hengrui Pharmaceuticals Gets China Nod to Trial Two Tumor Drugs

MT Newswires Live

Hengrui Pharma to Close H-Share Register Ahead of 24 September 2026 Extraordinary Meeting

Bulletin Express

HENGRUI PHARMA Advances Pipeline with SHR-1179 Injection Clinical Trial Approval

BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.21% on SEP 2 from 5.92% - HKEX

THOMSON REUTERS

Hengrui Pharma Subsidiary Gains Clinical Trial Approval for Weight Management Drug Candidate

August Buyback Report: 277 A-Share Firms Spend Over 13 Billion Yuan, More Than Half Beat the Shanghai Composite, Gaozheng Explosive Surges 68% in a Month

Evaluating the Potential Value of Hengrui's HRS-9531 in an Intensifying GIP Competitive Landscape

Hengrui Pharmaceuticals Gets China Regulatory Acceptance for Atopic Dermatitis Drug Application

MT Newswires Live

Update: Hengrui Pharma Unit Secures China Nod For Diabetes Drug Application

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/01276/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":48.44,"timestamp":1791446897003,"preClose":49.14,"halted":0,"volume":7707759,"delay":0,"changeRate":-0.014245014245014303,"floatShares":258000000,"shares":6637000000,"eps":1.3814096577487227,"marketStatus":"Not Yet Opened","change":-0.7,"latestTime":"10-08 16:08:17","open":49.74,"high":51,"low":48.28,"amount":381006025,"amplitude":0.055352,"askPrice":48.44,"askSize":30800,"bidPrice":48.4,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.3623157666318737,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":49.14,"dividendRate":0.004829,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"volumeRatio":1.556397,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":47.01,"timestamp":1791442800000,"preClose":47.2,"halted":0,"volume":77344000,"delay":0,"premium":"-11.98"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"7.02%","roe":"12.46%","lyrEps":1.38141,"volumeRatio":1.556397,"shares":6637000000,"dividePrice":0.234137,"high":51,"amplitude":0.055352,"preClose":49.14,"low":48.28,"week52Low":43.02,"pbRate":"4.26","psRate":"8.77","week52High":91.88,"institutionHeld":0,"latestPrice":48.44,"committee":-0.987097,"eps":1.3814096577487227,"divideRate":0.004834,"volume":7707759,"delay":0,"ttmEps":1.3623157666318737,"open":49.74,"prevYearClose":71.002,"prevWeekClose":49.66,"prevMonthClose":50.2,"prevQuarterClose":50.2,"fiveDayClose":50.2,"twentyDayClose":45.94,"sixtyDayClose":58.45,"earningDate":1793116800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1793151000000,"name":null,"time":"","dateTimestamp":1793116800000,"actualEps":null},{"date":"2026-08-19","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787103000000,"name":null,"time":"","dateTimestamp":1787068800000,"actualEps":null},{"date":"2026-04-29","symbol":"01276","amount":0.22828,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-04-30","defaultRemindTime":1777426200000,"name":"恒瑞医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-27","payableDate":"2026-04-30","currency":"HKD","dateTimestamp":1777392000000,"payDate":"2026-05-27"},{"date":"2026-04-22","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776821400000,"name":null,"time":"","dateTimestamp":1776787200000,"actualEps":null},{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[{"executeDate":"2026-04-29","recordDate":"2026-04-30","paymentDate":"2026-05-27","value":0.22828,"currency":"HKD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.5455,"hold":0.1818,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-10-07","current":35.557102,"percent":0.138235,"low":36.382401,"twenty":43.078413,"median":51.356483,"eighty":56.807294,"high":65.582363,"avg":50.578041,"sd":7.710556,"marketCap":364150510612.46},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-20","current":48.948437,"twenty":51.671435,"median":55.086674,"eighty":60.515374,"marketCap":414967977646.95},{"date":"2026-03-27","current":47.483832,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"marketCap":414588875872.42},{"date":"2026-04-02","current":49.302243,"twenty":51.107295,"median":54.905743,"eighty":60.227005,"marketCap":432534434303.11},{"date":"2026-04-10","current":49.055344,"twenty":50.995993,"median":54.897923,"eighty":60.186394,"marketCap":433687668394.36},{"date":"2026-04-17","current":48.417764,"twenty":50.589497,"median":54.65026,"eighty":60.143018,"marketCap":428230701835.75},{"date":"2026-04-24","current":45.835792,"twenty":50.342877,"median":54.475147,"eighty":60.015062,"marketCap":426879682872.04},{"date":"2026-04-30","current":44.026312,"twenty":50.285416,"median":54.355253,"eighty":59.903394,"marketCap":410132737659.64},{"date":"2026-05-08","current":43.161515,"twenty":50.207478,"median":54.262074,"eighty":59.804539,"marketCap":403472171949.3},{"date":"2026-05-15","current":44.128138,"twenty":49.985706,"median":54.115335,"eighty":59.70386,"marketCap":413593092820.6},{"date":"2026-05-22","current":41.244553,"twenty":49.583265,"median":53.983854,"eighty":59.631568,"marketCap":385683097978.4},{"date":"2026-05-29","current":40.98659,"twenty":49.34142,"median":53.840414,"eighty":59.564678,"marketCap":384603594259.51},{"date":"2026-06-05","current":38.394132,"twenty":49.063316,"median":53.633194,"eighty":59.459458,"marketCap":360799766229.36},{"date":"2026-06-12","current":39.515262,"twenty":48.81081,"median":53.517715,"eighty":59.36625,"marketCap":371084155232.86},{"date":"2026-06-18","current":39.444808,"twenty":48.417764,"median":53.467699,"eighty":59.301536,"marketCap":371311256576.18},{"date":"2026-06-26","current":39.60241,"twenty":47.951326,"median":53.090114,"eighty":59.187086,"marketCap":370974287810.31},{"date":"2026-07-03","current":44.319925,"twenty":47.638943,"median":53.015805,"eighty":59.069259,"marketCap":415476044901.86},{"date":"2026-07-10","current":45.319748,"twenty":47.348429,"median":52.993744,"eighty":59.024871,"marketCap":424327469311.14},{"date":"2026-07-17","current":43.189222,"twenty":46.151454,"median":52.805265,"eighty":58.96135,"marketCap":405818502739.33},{"date":"2026-07-24","current":43.433009,"twenty":45.632553,"median":52.604835,"eighty":58.912251,"marketCap":408200902707.63},{"date":"2026-07-31","current":43.935338,"twenty":45.29749,"median":52.543618,"eighty":58.877468,"marketCap":413706414238.87},{"date":"2026-08-07","current":44.394532,"twenty":45.008473,"median":52.339287,"eighty":58.813302,"marketCap":418841988303.56},{"date":"2026-08-14","current":42.6704,"twenty":44.628794,"median":52.189578,"eighty":58.452058,"marketCap":403085247281.44},{"date":"2026-08-21","current":40.686911,"twenty":44.408765,"median":52.120101,"eighty":57.75211,"marketCap":366558497066.13},{"date":"2026-08-28","current":40.334802,"twenty":44.24321,"median":51.814807,"eighty":57.336246,"marketCap":363468645736.13},{"date":"2026-09-04","current":39.220129,"twenty":44.050964,"median":51.771686,"eighty":57.152374,"marketCap":353565883607.49},{"date":"2026-09-11","current":36.382401,"twenty":43.912617,"median":51.717719,"eighty":57.022157,"marketCap":328426636361.34},{"date":"2026-09-18","current":37.472943,"twenty":43.707258,"median":51.677141,"eighty":56.974512,"marketCap":338713028678.65},{"date":"2026-09-25","current":38.226655,"twenty":43.43262,"median":51.617827,"eighty":56.891919,"marketCap":344867204477.93},{"date":"2026-10-02","current":40.279147,"twenty":43.172598,"median":51.438629,"eighty":56.828798,"marketCap":363767175425.28},{"date":"2026-10-07","current":40.264098,"twenty":43.078413,"median":51.356483,"eighty":56.807294,"marketCap":364150510612.46}],"updateTime":1791483277750},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1152020231","title":"Movement Alert｜HENGRUI PHARMA Rises 3.2% in Regular Trading, Core ADC Pipeline Drug Included in Breakthrough Therapy Designation List","url":"https://stock-news.laohu8.com/highlight/detail?id=1152020231","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152020231?lang=en_us&edition=fundamental","pubTime":"2026-09-14 14:27","pubTimestamp":1789367244,"startTime":"0","endTime":"0","summary":"On September 14, HENGRUI PHARMA rose 3.2% in regular trading, trading at HK$45.16/share, with turnover of approximately HK$86.20 million. The gain was driven by a recent announcement that the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"HENGRUI PHARMA Gains as HER3 ADC Gets Breakthrough Therapy Tag","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667263452","title":"Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List","url":"https://stock-news.laohu8.com/highlight/detail?id=2667263452","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667263452?lang=en_us&edition=fundamental","pubTime":"2026-09-14 10:45","pubTimestamp":1789353956,"startTime":"0","endTime":"0","summary":"China's drug regulator included Jiangsu Hengrui Pharmaceuticals  subsidiary Suzhou Shengdia Biopharmaceutical's ruzaltatug rezetecan drug for non-small cell lung cancer in its breakthrough therapy designation list, according to a Saturday filing with the Shanghai bourse.The drug is indicated for combination with bevacizumab to treat advanced or metastatic non-squamous non-small cell lung cancer with epidermal growth factor receptor tyrosine kinase inhibitors, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1820825898.SGD","BK0028","BK0060","BK0196","LU1997245094.SGD","BK0012","LU2148510915.USD","LU2543165471.USD","LU0359202008.SGD","LU1255011170.USD","LU1146622755.USD","LU1328615791.USD","LU1969619763.USD","LU1023057109.AUD","LU2328871848.SGD","LU2495084118.USD","LU0359201885.HKD","BK1191","01276","LU2097828631.EUR","LU1997244956.HKD","LU2097828805.USD","LU1580142542.USD","LU1064131003.USD","LU2097828714.EUR","BK0188","LU2097828557.USD","LU0405327148.USD","LU2289578879.USD","LU1064130708.USD","LU0359201612.USD","LU0405327494.USD","600276","LU2097828474.EUR","LU2488822045.USD","LU1781817850.SGD","LU2580892789.USD","LU1655091616.SGD","LU1997245177.USD","BK0183","LU2580892862.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666737560","title":"Hengrui Pharma Gets China Nod for Two Indications of Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2666737560","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666737560?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:23","pubTimestamp":1789039426,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  obtained approval for two new indications of its Hetrombopag Olamine Tablets from China's  National Medical Products Administration.The first indication is for the treatment of adult patients with thrombocytopenia caused by chemotherapy-based anti-tumor therapy for solid tumors, according to a Thursday bourse filing.The other indication is for pediatric patients over six years of age with chronic primary immune thrombocytopenia.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023057109.AUD","LU0359201612.USD","01276","LU0359202008.SGD","LU0359201885.HKD","BK1191","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666679065","title":"Jiangsu Hengrui Pharmaceuticals Co - Nmpa Approves Two New Indications for Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2666679065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666679065?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:46","pubTimestamp":1789037160,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0359202008.SGD","LU1023057109.AUD","BK0060","BK0239","LU2488822045.USD","LU2328871848.SGD","LU2495084118.USD","LU2148510915.USD","BK0196","LU1969619763.USD","600276","LU2097828557.USD","LU2580892862.HKD","LU0405327494.USD","LU1064130708.USD","LU1781817850.SGD","LU2289578879.USD","LU1820825898.SGD","LU1328615791.USD","LU1064131003.USD","BK0183","LU1655091616.SGD","LU2097828474.EUR","LU2580892789.USD","LU1255011170.USD","LU1997245177.USD","LU2097828714.EUR","LU0359201612.USD","LU2097828631.EUR","BK0012","01276","LU1146622755.USD","BK0188","LU0405327148.USD","BK1191","BK0028","LU0359201885.HKD","LU1580142542.USD","LU1997244956.HKD","LU1997245094.SGD","LU2543165471.USD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115847199","title":"Jiangsu Hengrui Pharmaceuticals Secures Regulatory Nod for Two New Indications of Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1115847199","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115847199?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:54","pubTimestamp":1789034083,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (600276.SH) has announced that it recently received notification from China's National Medical Products Administration, granting approval for two additional...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1255011170.USD","LU0405327494.USD","LU2328871848.SGD","LU2488822045.USD","LU1997244956.HKD","LU0405327148.USD","BK1191","LU2097828631.EUR","LU0359202008.SGD","LU2580892862.HKD","LU2543165471.USD","LU1064131003.USD","600276","LU1146622755.USD","LU1064130708.USD","BK0012","BK0239","LU1023057109.AUD","BK0028","BK0183","LU0359201612.USD","LU2097828557.USD","LU2097828805.USD","BK0188","LU2148510915.USD","01276","LU1781817850.SGD","LU2097828474.EUR","LU1997245094.SGD","LU0359201885.HKD","LU1969619763.USD","BK0060","LU1328615791.USD","LU2289578879.USD","LU2580892789.USD","LU1820825898.SGD","LU2097828714.EUR","BK0196","LU1997245177.USD","LU1580142542.USD","LU2495084118.USD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143529951","title":"Movement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1143529951","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143529951?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:48","pubTimestamp":1789008515,"startTime":"0","endTime":"0","summary":"On September 10, HENGRUI PHARMA fell 3.13% in regular trading, trading at HK$44.5/share, with turnover of HK$51.87 million.The decline came amid a broad selloff across the pharmaceuticals sector,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Hengrui Falls Amid Pharma Selloff Despite NMPA Drug Filing","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666551019","title":"China Accepts Hengrui Pharma Unit's Marketing Application for Diabetes Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551019","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551019?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:45","pubTimestamp":1789008337,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the marketing application of Jiangsu Hengrui Pharmaceuticals'  unit, Fujian Shengdi Pharmaceutical, for repaglinide, according to a Thursday disclosure on the Shanghai bourse.The drug is indicated for glycemic control in adult patients with type 2 diabetes mellitus.The pharmaceutical company's shares fell 3% during the morning trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359201612.USD","BK1191","LU0359201885.HKD","01276","LU2543165471.USD","LU0359202008.SGD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194600066","title":"AH Share Premium Rankings as of September 9 Trading Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1194600066","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194600066?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:24","pubTimestamp":1788942275,"startTime":"0","endTime":"0","summary":"As of the market close on September 9, three companies lead the A-H share premium rankings for the session. NE ELECTRIC (00042) tops the list with a premium of 1121.72%, followed by ZHEJIANG SHIBAO...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1564","BK1223","LU1023057109.AUD","03678","SG9999002463.SGD","LU1813983027.USD","LU0417516902.SGD","00895","BK1249","LU1961090484.USD","01812","LU0828238088.HKD","BK1583","LU0106959298.USD","BK1149","IE00BZ08YS42.EUR","HK0000320264.USD","BK1198","HK0000320223.HKD","02899","LU0128522157.USD","HK0001040143.USD","LU0149534421.HKD","LU0329678170.USD","LU1328277881.USD","SG9999014674.SGD","BK1544","BK1116","LU1188198961.HKD","LU2177674079.SGD","LU1242518931.SGD","03130","LU1655091616.SGD","LU2097828474.EUR","SG9999001093.SGD","BK1190","LU0531971595.HKD","LU1244550577.SGD","LU1504937902.USD","BK1592","03986","LU1481107354.HKD","LU0359201612.USD","00553","LU0918141705.HKD","06869","LU1152091754.HKD","SG9999004220.SGD","LU0469268626.HKD","LU0320764599.SGD","LU0561508036.HKD","LU0328353924.USD","BK1191","00317","LU0082770016.SGD","LU0039217434.USD","BK1523","BK1537","LU0266512473.USD","LU1769817096.USD","LU2242644610.SGD","LU2264538146.SGD","LU2543165471.USD","LU2226246903.HKD","BK1202","LU1152091168.USD","LU0370786039.SGD","LU2399975544.HKD","00300","LU0165289439.USD","LU0048580855.USD","IE00BZ08YR35.GBP","LU0314109678.HKD","HK0000306701.USD","LU0266512127.USD","LU0049853897.USD","BK1170","LU1831875114.USD","BK1237","BK1594","BK1562","03200","BK1522","LU0828237940.HKD","LU0431992006.USD","BK1515","LU2394011477.USD","BK1554","LU0868486357.SGD","BK1171","LU0449509016.USD","BK1514","LU0634319403.HKD","LU0348825331.USD","LU1769817179.HKD","LU0540923850.HKD","IE0032431581.USD","06745","LU0287142896.SGD","LU1255011170.USD","LU1282648689.USD","LU1770034418.SGD","LU0149721374.USD","IE00BZ08YT58.USD","83130","LU0307460666.USD","BK1533","LU0348816934.USD","BK1193","LU1046422090.SGD","LU0672654166.SGD","02475","LU0588546209.SGD","01033","LU0359201885.HKD","LU2039709279.SGD","LU0348827113.USD","LU0821914370.USD","159982","LU0043850808.USD","00187","LU1807302812.USD","LU2097828805.USD","LU0359202008.SGD","BK1105","LU0417516738.SGD","LU0140636845.USD","LU1244550494.USD","SG9999001226.SGD","00991","BK1610","02846","LU0345780281.USD","LU0886674414.USD","LU0979878070.USD","LU0531970944.HKD","03308","BK1551","LU0164865239.USD","LU0096374516.USD","LU1242518857.USD","LU2125910500.SGD","BK1505","09976","82846","LU1794554557.SGD","02359","LU1988902786.USD","LU0456854461.SGD","LU0463099449.HKD","LU0348766576.USD","BK1148","BK1546","BK1125","BK1576","LU0880133367.SGD","LU0214875030.USD","01877","00042","LU1105468828.SGD","LU1719994722.HKD","LU0620787316.HKD","LU1808992512.USD","02827","03328","BK1110","BK1214","BK1141","LU0327786744.USD","LU0345780521.USD","LU0348767384.USD","LU1244550221.USD","LU3063872942.SGD","LU1960683339.HKD","SG9999006597.SGD","06066","LU0320764755.SGD","LU0052750758.USD","LU0348735423.USD","LU0082770016.USD","06821","02218","BK1163","LU0106252389.USD","02068","LU0029875118.USD","BK1140","LU2008162690.USD","03188","LU0164939612.USD","01057","LU0173614495.USD","07233","LU0181495838.USD","BK1560","LU0164880469.USD","LU1251922891.USD","LU0061477393.USD","LU0254981946.USD","02865","BK1183","LU0228659784.USD","LU2097828557.USD","HK0000306685.HKD","LU0211977185.USD","LU0607220059.USD","LU1206782309.USD","LU0708995583.HKD","BK1552","03750","BK1231","BK1161","LU0269904917.USD","LU0348814723.USD","SG9999011746.SGD","LU1048596156.SGD","BK1506","LU1064131342.USD","01108","83188","LU0509642566.USD","LU2045819591.USD","LU0797268264.HKD","EWH","LU0918141887.USD","LU1224709979.USD","LU1993786604.SGD","IE0034224299.USD","01349","IE00B0169L03.USD","HK0001040168.HKD","LU0067412154.USD","BK1530","LU0543330483.HKD","LU2097828714.EUR","LU2097828631.EUR","LU0871576103.HKD","BK1147","01276","LU0329678337.USD","LU0326950275.SGD","LU1008478684.HKD","02338","LU0244354667.USD","LU0737861772.HKD","399300","LU1303224171.USD","BK1144","LU1720050803.USD","LU0572944931.SGD","LU0737861699.HKD","BK1122","LU0828237510.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180880506","title":"Hengrui Pharma Sets 24 Sep 2026 EGM to Vote on Dual Employee Share Schemes and 10% H-Share Buyback Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1180880506","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180880506?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868892,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) has issued the proxy form for its 2026 First Extraordinary Shareholders’ Meeting (EGM), scheduled for 2:30 p.m. on Thursday, 24 September...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136946420","title":"Hengrui Pharma Seeks Approval for 2026 Dual-Class Incentive Plans and 10% H-Share Buy-Back Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1136946420","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136946420?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:43","pubTimestamp":1788867786,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) has issued a circular convening its first extraordinary shareholders’ meeting for 24 September 2026 to vote on a suite of capital and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665234138","title":"Hengrui Pharma Wins China Clinical Trial Nod For Two Weight Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2665234138","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665234138?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:19","pubTimestamp":1788837571,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  subsidiaries received clinical trial approval from China's National Medical Products Administration for two weight management tablets, HRS-1597 and SHR-1179, according to separate Tuesday filings with the Shanghai bourse.Research and development investment for the HRS-1597 product so far reached 16.9 million yuan, while that for SHR-1179 is at 24.2 million yuanThe drug company's Hong Kong and Shanghai shares slipped 1% during Tuesday's morning session.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023057109.AUD","BK0196","LU2097828557.USD","LU2328871848.SGD","BK0060","LU2495084118.USD","LU2097828805.USD","LU2488822045.USD","LU2580892862.HKD","LU0359201885.HKD","LU2543165471.USD","LU1255011170.USD","LU1064131003.USD","LU1969619763.USD","LU1997245094.SGD","LU2097828714.EUR","LU1997245177.USD","LU0405327494.USD","LU1820825898.SGD","LU2580892789.USD","LU1655091616.SGD","LU1328615791.USD","LU0359202008.SGD","BK1191","BK0012","LU0405327148.USD","LU2148510915.USD","01276","600276","LU1580142542.USD","LU0359201612.USD","BK0239","LU1781817850.SGD","LU2097828631.EUR","LU1064130708.USD","LU2097828474.EUR","BK0183","LU1997244956.HKD","LU1146622755.USD","LU2289578879.USD","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665341844","title":"Hengrui Pharmaceuticals Gets China Nod to Trial Two Tumor Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665341844","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665341844?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:17","pubTimestamp":1788837431,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  obtained approval from China's National Medical Products Administration for the clinical trials of HRS-6209 capsules and HRS-4508 tablets, according to a Shanghai bourse filing on Tuesday.HRS-6209 is a novel selective CDK4 inhibitor that is clinically intended for the treatment of advanced malignant solid tumors, while HRS-4508 is a tyrosine kinase inhibitor that inhibits the proliferation of tumor cells.The pharmaceutical company has invested 160.9 million yuan into the research and development of HRS-6209 and 96.7 million yuan in HRS-4508's research.Hengrui's Shanghai and Hong Kong shares both slipped 1% during the morning trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0405327148.USD","LU0359201612.USD","LU2543165471.USD","LU1781817850.SGD","LU0359202008.SGD","BK0183","BK0060","LU1820825898.SGD","LU2097828474.EUR","LU2580892789.USD","LU1997245094.SGD","LU2097828714.EUR","LU1328615791.USD","LU2289578879.USD","BK0188","LU0405327494.USD","LU1997244956.HKD","LU1064130708.USD","LU2495084118.USD","LU1064131003.USD","LU1969619763.USD","LU2097828557.USD","01276","LU2097828805.USD","LU1655091616.SGD","BK1191","LU2148510915.USD","BK0028","LU1023057109.AUD","BK0012","LU1146622755.USD","LU1580142542.USD","LU2097828631.EUR","BK0196","LU1255011170.USD","600276","LU2580892862.HKD","LU2328871848.SGD","LU2488822045.USD","LU1997245177.USD","BK0239","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149270469","title":"Hengrui Pharma to Close H-Share Register Ahead of 24 September 2026 Extraordinary Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1149270469","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149270469?lang=en_us&edition=fundamental","pubTime":"2026-09-07 19:03","pubTimestamp":1788778985,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) will convene its first extraordinary shareholders’ meeting for 2026 at 2:30 p.m. on Thursday, 24 September 2026, in Pudong New Area,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187160052","title":"HENGRUI PHARMA Advances Pipeline with SHR-1179 Injection Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1187160052","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187160052?lang=en_us&edition=fundamental","pubTime":"2026-09-07 18:52","pubTimestamp":1788778333,"startTime":"0","endTime":"0","summary":"Hengrui Pharma (01276) has announced that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd., has recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU0359201612.USD","BK1191","LU1655091616.SGD","LU1997245177.USD","LU2495084118.USD","LU2097828474.EUR","BK0196","LU1146622755.USD","LU1328615791.USD","LU1820825898.SGD","LU2148510915.USD","LU0405327494.USD","LU1997245094.SGD","LU2328871848.SGD","PSYK","LU2289578879.USD","LU1064130708.USD","LU2543165471.USD","LU2097828714.EUR","LU1969619763.USD","MDTX","BK0183","LU2580892862.HKD","BMED","LU2488822045.USD","LU1064131003.USD","LU2580892789.USD","01276","BK0028","LU0405327148.USD","LU1255011170.USD","LU1023057109.AUD","BK0239","BK0188","BK0060","LU0359201885.HKD","LU1997244956.HKD","LU1781817850.SGD","IBBJ","LU2097828631.EUR","LU1580142542.USD","IBBQ","BK0012","LU0359202008.SGD","600276","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665726313","title":"BlackRock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.21% on SEP 2 from 5.92% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2665726313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665726313?lang=en_us&edition=fundamental","pubTime":"2026-09-07 17:47","pubTimestamp":1788774474,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nFWN44W0Z9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","BK0188","LU2289578879.USD","LU0359201885.HKD","LU1997244956.HKD","LU0405327148.USD","LU2097828631.EUR","LU1255011170.USD","LU1997245094.SGD","LU1064130708.USD","BK0196","LU2148510915.USD","LU2328871848.SGD","01276","LU1023057109.AUD","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU0359202008.SGD","BK0012","LU1146622755.USD","BK0028","BK0239","BK1191","600276","LU0405327494.USD","LU2580892862.HKD","LU2097828474.EUR","BK0060","LU1328615791.USD","LU0359201612.USD","LU1781817850.SGD","LU1969619763.USD","LU1580142542.USD","LU2580892789.USD","LU1655091616.SGD","LU2495084118.USD","LU1997245177.USD","LU2097828805.USD","BK0183","LU1820825898.SGD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110897642","title":"Hengrui Pharma Subsidiary Gains Clinical Trial Approval for Weight Management Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1110897642","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110897642?lang=en_us&edition=fundamental","pubTime":"2026-09-07 17:22","pubTimestamp":1788772938,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SH: 600276) has announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., recently received the Drug Clinical Trial Approval Notice issued...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1655091616.SGD","LU0405327148.USD","LU2328871848.SGD","600276","LU0359201612.USD","LU2580892862.HKD","BK0196","LU1146622755.USD","LU1997244956.HKD","LU2495084118.USD","LU2543165471.USD","PSYK","BK0012","LU2097828714.EUR","LU1023057109.AUD","BK0060","LU2097828631.EUR","BK0028","LU2097828557.USD","LU1820825898.SGD","LU1064131003.USD","LU1997245094.SGD","01276","LU0359201885.HKD","LU1255011170.USD","BK1191","LU1580142542.USD","LU1064130708.USD","LU0405327494.USD","LU2148510915.USD","MDTX","LU2097828474.EUR","BMED","IBBQ","BK0183","BK0239","LU2488822045.USD","IBBJ","LU1997245177.USD","LU1969619763.USD","LU2580892789.USD","LU2289578879.USD","LU2097828805.USD","LU1781817850.SGD","LU0359202008.SGD","LU1328615791.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161797164","title":"August Buyback Report: 277 A-Share Firms Spend Over 13 Billion Yuan, More Than Half Beat the Shanghai Composite, Gaozheng Explosive Surges 68% in a Month","url":"https://stock-news.laohu8.com/highlight/detail?id=1161797164","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161797164?lang=en_us&edition=fundamental","pubTime":"2026-09-05 17:02","pubTimestamp":1788598952,"startTime":"0","endTime":"0","summary":"Data from Tonghuashun iFinD reveals that approximately 277 listed companies executed share buybacks in August, with combined monthly spending surpassing 13 billion yuan. Midea Group Co.,Ltd. (SZSE:...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1655091616.SGD","LU2097828557.USD","BK0028","BK0224","LU0784639295.USD","LU0228659784.USD","LU0880133367.SGD","LU1997245094.SGD","LU0708995583.HKD","LU2476274308.USD","IE00B29SXG58.USD","LU0456842615.SGD","BK0033","IE00BZ08YR35.GBP","LU2097828714.EUR","IE0008368411.USD","LU1979443071.USD","LU0831103253.SGD","IE0031814852.USD","LU1146622755.USD","LU0898667661.SGD","LU0955648018.USD","LU0396098781.USD","IE00BZ08YT58.USD","LU0320764599.SGD","LU2580892862.HKD","IE00B97KM107.HKD","LU2097828474.EUR","LU0791590937.USD","LU0052750758.USD","LU0264606111.USD","LU1655091459.SGD","IE00BZ08YS42.EUR","BK0201","LU1226287529.USD","LU0828238088.HKD","LU1568876335.HKD","LU1255011170.USD","LU0501845795.SGD","BK0183","IE00B031J352.USD","LU0509642566.USD","LU2495084118.USD","LU1048484197.HKD","IE00B031HW06.USD","BK0070","LU1366334578.USD","BK0061","LU0117844026.USD","LU0862451753.SGD","LU2097828631.EUR","LU1997245177.USD","LU1328615791.USD","LU1934453819.USD","LU0791591158.USD","BK0077","LU0955623706.USD","LU2213484517.USD","600227","BK0026","IE00BPRC5H50.USD","LU1366334651.USD","LU0210527791.USD","IE0003851619.USD","LU1130305938.SGD","LU1580142542.USD","LU2778985437.USD","LU1997244956.HKD","LU0862451837.USD","BK0214","LU1568876251.USD","LU0572940350.SGD","LU1064130708.USD","01276","IE00B5MMRT66.SGD","BK0056","BK0239","IE00B0JY6N72.USD","LU2580892789.USD","LU2097828805.USD","IE0008368742.USD","LU0593848301.USD","BK0012","LU0572939691.SGD","LU2506952253.HKD","LU0405327494.USD","00300","002913","BK0066","LU1039395188.USD","LU1675838814.USD","LU0231483743.USD","BK0278","IE0009570106.USD","LU1807302812.USD","000333","IE00B8L5B284.USD","BK0229","BK0175","LU0072913022.USD","LU1969619763.USD","000001","BK0187","LU2488822045.USD","LU0269904917.USD","LU1064131003.USD","LU0955669360.SGD","LU1781817850.SGD","IE0003795394.USD","LU0067412154.USD","LU2148510915.USD","LU2289578879.USD","LU0823437842.USD","002827","IE00B031HY20.USD","IE00B543WZ88.USD","LU1993786604.SGD","IE0005HP3H50.USD","LU0405327148.USD","BK0196","IE00B8HQ1Z84.USD","LU1820825898.SGD","IE00BKZH1Z71.USD","LU0890818403.SGD","BK0188","LU2328871848.SGD","IE00B067MR52.USD","600276","IE0032834883.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126407744","title":"Evaluating the Potential Value of Hengrui's HRS-9531 in an Intensifying GIP Competitive Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=1126407744","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126407744?lang=en_us&edition=fundamental","pubTime":"2026-09-04 15:32","pubTimestamp":1788507126,"startTime":"0","endTime":"0","summary":"The valuation of innovative pharmaceutical companies is fundamentally anchored in the value of their pipeline assets. As a core candidate in Hengrui's metabolic disease franchise, the clinical...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","LU1328615791.USD","LU1064130708.USD","LU1820825898.SGD","01276","LU0405327148.USD","LU2328871848.SGD","LU0359202008.SGD","BK0188","LU2289578879.USD","LU1781817850.SGD","LU0359201612.USD","LU1255011170.USD","LU2097828474.EUR","LU2097828805.USD","LU2097828557.USD","LU2148510915.USD","LU2488822045.USD","LU1580142542.USD","BK0183","LU0359201885.HKD","BK0060","LU2097828714.EUR","BK0028","LU2097828631.EUR","LU2580892862.HKD","LU0405327494.USD","BK1191","LU1146622755.USD","LU1997245094.SGD","LU1064131003.USD","LU1997245177.USD","LU2543165471.USD","BK0196","LU1969619763.USD","LU2495084118.USD","BK0239","BK0012","600276","LU1655091616.SGD","LU2580892789.USD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664138343","title":"Hengrui Pharmaceuticals Gets China Regulatory Acceptance for Atopic Dermatitis Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2664138343","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664138343?lang=en_us&edition=fundamental","pubTime":"2026-09-04 10:19","pubTimestamp":1788488392,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  unit Guangdong Hengrui Medicine obtained China's regulatory acceptance for the marketing authorization application of SHR-1819 injection.The drug is indicated for moderate-to-severe atopic dermatitis in adults, according to a Friday filing with the Shanghai bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01276","LU0359201885.HKD","LU0359201612.USD","LU2543165471.USD","LU0359202008.SGD","LU1023057109.AUD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818823","title":"Update: Hengrui Pharma Unit Secures China Nod For Diabetes Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818823","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818823?lang=en_us&edition=fundamental","pubTime":"2026-09-03 10:24","pubTimestamp":1788402243,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  unit Shandong Shengdi received regulatory acceptance in China for the marketing application of its HRS-7535 tablets.The drug is indicated for blood sugar control in patients with type two diabetes mellitus, according to a Wednesday aftermarket filing with the Shanghai bourse.Shares of the company were up 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2543165471.USD","BK1191","LU0359201612.USD","LU0359202008.SGD","01276","LU1023057109.AUD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}